Syngene confirms biologics expansion with new bioconjugation capability

Syngene International Limited issued a clarification on October 23, 2025, confirming information from a news article titled, "Syngene expands Biologics facility with new ADC bioconjugation capability." The company stated its plans to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs), covering discovery through GMP manufacturing. This new suite aims to accelerate development timelines by enabling monoclonal antibody (mAb) production and GMP bioconjugation at a single site, complementing existing commercial capabilities in payload and linker manufacturing.

The investment in bioconjugation capabilities is considered to be in the ordinary course of business and is not deemed "material" under current materiality criteria. This information addresses an email dated October 23, 2025, seeking clarification on the matter.

Further details regarding this announcement will be made available on the company's website. The communication was signed by chethan yogesh, company secretary & compliance officer.